Virpax Pharmaceuticals Inc., a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) for Epoladerm (diclofenac epolamine) spray.   Epoladerm is being developed in partnership with MedPharm Ltd, a contract provider of topical and transdermal product design and formulation development services. Epoladerm ...